Olaf Stuve, M.D., Ph.D.

Chief of Neurology, Dallas Veterans Affairs Medical Center

Neurology

Biography

Dr. Olaf Stuve is a Professor in the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center in Dallas, and Chief of Neurology at the VA North Texas Health Care System/ Dallas VA Medical Center. In addition to his clinical activities, he has been the site Principal Investigator and Consultant for numerous clinical trials. He also runs a research laboratory at UT Southwestern. His research interests include molecular and cellular markers of autoimmunity, immune tolerance, and experimental therapies for autoimmune disorders, and he has numerous ongoing collaborations with national and international investigators. He has mentored undergraduate students, graduate students, medical students, residents, and post-doctoral fellows.

Dr. Stuve’s research has been supported by grants from the Department of Veterans Affairs, the National Multiple Sclerosis Society (NMSS), the Deutsche Forschungsgemeinschaft (DFG), Boehringer Ingelheim Fonds, and the Doris Duke Charitable Foundation. He has published over 200 research articles, review articles, editorials, and book chapters.

Dr. Stuve is a fellow of the American Neurological Association (FANA), and the American Academy of Neurology (FAAN). He is an elected member of the Alpha Omega Alpha (AOA) Honor Medical Society.

He has served on numerous editorial boards of medical and scientific journals, and has been a member of National Institutes of Health (NIH), and NMSS study sections. Dr. Stuve is a past associate editor of JAMA Neurology, and a past steering committee member of the Immune Tolerance Network (ITN).

He received his medical degree from the Free University of Berlin, completed a medical doctoral thesis in physiology at the Max Delbruck Center for Molecular Medicine in Berlin magna cum laude, and earned a Ph.D. in immunology in the Department of Clinical and Experimental Immunology at Maastricht University. He completed a transitional internship at the University of Cape Town, and a preliminary internship and neurology residency at the University of Washington in Seattle. Dr. Stuve also received postdoctoral fellowship training in neuroimmunology at McGill University in Montreal, and at the University of California, San Francisco (UCSF).

Dr. Stuve has received numerous clinical teaching awards and was included in D Magazine's Best Doctors list for 2018.

Education & Training

Medical School - Freie University Berlin, Medicine
Medical School - Max Delbruck Center for Molecu, Physiology
Graduate School - Maastricht University, Immunology

Honors & Awards

Magna cum laude M.D. thesis 1994, Free University of Berlin, Germany
Postdoctoral fellowship grant 1995, Deutsche Forschungsgemeinschaft (DFG), Germany
H.-L. Teuber price 1996, The Montreal Neurological Institute, McGill University, Montreal
Advanced postdoctoral fellowship grant 2000, National Multiple Sclerosis Society (NMSS)
Postdoctoral scholarship 2001, Boehringer Ingelheim Fonds
Clinical Scientist Development Award 2009, Doris Duke Charitable Foundation
Clinical Teaching Award Neurology 2007, University of Texas Southwestern Medical School, Class of 2008
Alpha Omega Alpha (ΑΩΑ) Honor Medical Society 2013, Honorary member, Texas Gamma Chapter

Books & Publications

Publications
- The Knowns and Unknowns of Prion Protein in Immune Modulation and the Pathogenesis of Neuroautoimmune Diseases
  Abbasi Kasbi N, Stuve O Current Treatment Options in Neurology 2025 Dec 27
- Tau in Multiple Sclerosis: A Review of Therapeutic Potential
  Hoehne C, Stuve O, Stopschinski BE Current Treatment Options in Neurology 2025 Dec 27
- Multiple sclerosis treatments a review of current biomedical engineering approaches
  Mohseni SO, Au KM, Issa W, Ruan L, Stuve O, Wang AZ Biomaterials 2025 Feb 313
- Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
  Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D The Lancet Neurology 2024 Nov 23 1119-1132
- Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome
  Author Collaboration ob, Okuda DT, Azevedo CJ, Pelletier D, Moog TM, Moazami S, Rezvani S, Bovis F, Sormani MP, Siva A, Kantarci O, Lebrun-Frénay C, Vargas WS, Stüve O, Repovic P, Pardo G, Okuda DT, Okai A, Naismith RT, Mowry EM, Hua LH, Donlon S, Azevedo CJ, Amezcua L Journal of neurology 2024 Sep 271 5899-5910
- A T_H17-intrinsic IL-1β–STAT5 axis drives steroid resistance in autoimmune neuroinflammation
  Miller-Little WA, Chen X, Salazar V, Liu C, Bulek K, Zhou JY, Li X, Stüve O, Stappenbeck T, Dubyak G, Zhao J, Li X Science Immunology 2024 May 9
- Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
  Shirani A, Stuve O, Cross AH Neurologic Clinics 2024 Feb 42 137-153
- Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy
  Shirani A, Saez-Calveras N, Antel JP, Yaqubi M, Moore W, Brewster AL, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
- The immunology and pathophysiology of multiple sclerosis
  Calveras NS, Stuve O 2024 Jan 3-36
- Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
  Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
- Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
  Shirani A, Cross AH, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
- A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
  Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H Therapeutic Advances in Neurological Disorders 2024 Jan 17
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
  Shirani A, Cross AH, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
- Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)
  Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross A, Havrdova EK, Kappos L, Stuve O, Wiendl H, Wolinsky J, Bolay CL, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D Multiple Sclerosis and Related Disorders 2023 Dec 80
- T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
  Reder AT, Stuve O, Tankou SK, Leist TP Multiple Sclerosis Journal 2023 May 29 648-656
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
  Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D Annals of Neurology 2023 Mar 93 604-614
- Extended-interval dosing of natalizumab in NOVA
  Stüve O, Tugemann B The Lancet Neurology 2023 Mar 22 199-200
- Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity
  Manouchehri N, Salinas VH, Hussain RZ, Stüve O Proceedings of the National Academy of Sciences of the United States of America 2023 Feb 120
- Editorial: Animal models of multiple sclerosis: can they advance future therapies?
  DeSilva TM, Stuve O Frontiers in Molecular Neuroscience 2023 16
- Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
  Stopschinski BE, Weideman RA, McMahan D, Jacob DA, Little BB, Chiang HS, Saez Calveras N, Stuve O Therapeutic Advances in Neurological Disorders 2023 Jan 16
- Glial cell transcriptome analyses in 3xTg-AD mice: Effects of aging, disease progression, and anti-Aβ immunotherapy
  Lambracht-Washington D, Fu M, Manouchehri N, Hynan LS, Stuve O, Rosenberg RN Aging Brain 2023 Jan 3
- Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis
  Spain RI, Hildebrand A, Waslo CS, Rooney WD, Emmons J, Schwartz DL, Freedman MS, Paz Soldan MM, Repovic P, Solomon AJ, Rinker J, Wallin M, Haselkorn JK, Stuve O, Gross RH, Turner AP Frontiers in Neurology 2023 14
- Perspective: Industry–patient relationships for the promotion of pharmaceutical agents
  Bryarly MA, Rubin MA, Stuve O Therapeutic Advances in Neurological Disorders 2023 Jan 16
- Tau seeding in cases of multiple sclerosis
  LaCroix MS, Mirbaha H, Shang P, Zandee S, Foong C, Prat A, White CL, Stuve O, Diamond MI Acta Neuropathologica Communications 2022 Dec 10
- Toward Precision Phenotyping of Multiple Sclerosis
  Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR Neurology: Neuroimmunology and NeuroInflammation 2022 Nov 9
- The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review
  Saez-Calveras N, Brewster AL, Stuve O Frontiers in Molecular Neuroscience 2022 Oct 15
- The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
  Hussain RZ, Sguigna PV, Okai A, Wright C, Madinawala M, Bass AD, Cutter GR, Manouchehri N, Stuve O Journal of Central Nervous System Disease 2022 Aug 14
- The role of the complement system in Multiple Sclerosis: A review
  Saez-Calveras N, Stuve O Frontiers in immunology 2022 Aug 13
- Cognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature
  Chiang H, Khera A, Stopschinski BE, Stuve O, Hart J, Kelley B, Nguyen T Geriatrics (Switzerland) 2022 Jun 7
- Utilization of a neurology specialty service by primary care providers for headache management at a tertiary care hospital
  Vazirian S, Ho T, Weideman RA, Salinas MR, Hurd PW, Stuve O Journal of Central Nervous System Disease 2022 Jun 14
- To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
  Tugemann B, Manouchehri N, Stuve O Multiple Sclerosis and Related Disorders 2022 Mar 59
- Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
  Manouchehri N, Salinas VH, Rabi Yeganeh N, Pitt D, Hussain RZ, Stuve O Frontiers in Neurology 2022 Mar 13
- Clinical trials in multiple sclerosis: past, present, and future
  Manouchehri N, Shirani A, Salinas VH, Tardo L, Hussain RZ, Pitt D, Stuve O Neurologia i Neurochirurgia Polska 2022 56 228-235
- Choroid plexus volumetrics and brain inflammation in multiple sclerosis
  Manouchehri N, Stüve O Proceedings of the National Academy of Sciences of the United States of America 2021 Oct 118
- Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis
  Calvier L, Manouchehri N, Sacharidou A, Mineo C, Shaul PW, Hui DY, Kounnas MZ, Stüve O, Herz J Science Immunology 2021 Aug 6
- Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation
  Caldito NG, O’Leary S, Stuve O Multiple Sclerosis Journal 2021 Jul 27 1306-1308
- Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
  Caldito NG, Shirani A, Salter A, Stuve O Multiple Sclerosis Journal 2021 Jun 27 1066-1076
- The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo
  Manouchehri N, Guisso DR, Hussain RZ, Minassian BA, Stüve O Journal of Neuroimmunology 2021 May 354
- CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity
  Manouchehri N, Hussain RZ, Cravens PD, Esaulova E, Artyomov MN, Edelson BT, Wu GF, Cross AH, Doelger R, Loof N, Eagar TN, Forsthuber TG, Calvier L, Herz J, Stüve O Proceedings of the National Academy of Sciences of the United States of America 2021 Apr 118
- Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy
  Manouchehri N, Steinman L, Stuve O Neurology: Neuroimmunology and NeuroInflammation 2021 Mar 8 e935
- Systems approaches to unravel T cell function and therapeutic potential in autoimmune disease
  Salinas VH, Stuve O Journal of Immunology 2021 Feb 206 669-675
- Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
  Shirani A, Dalton SR, Avery EJ, Arcot Jayagopal L, Meyer C, Stuve O, Zabad R Journal of Central Nervous System Disease 2021 13
- Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
  Zhang Y, Salter A, Jin S, Culpepper WJ, Cutter GR, Wallin M, Stuve O Therapeutic Advances in Neurological Disorders 2021 14
- Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
  Manouchehri N, Stüve O Therapeutic Advances in Neurological Disorders 2021 14
- Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
  Negron A, Stüve O, Forsthuber TG Frontiers in Neurology 2020 Dec 11
- Sodium Phenylbutyrate-Taurursodiol for ALS
  Herz J, Stüve O The New England journal of medicine 2020 Dec 383 2294
- Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes
  Calvier L, Demuth G, Manouchehri N, Wong C, Sacharidou A, Mineo C, Shaul PW, Monson NL, Kounnas MZ, Stüve O, Herz J Science translational medicine 2020 Aug 12
- Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre⁺ITGA4^fl/fl mice
  Manouchehri N, Hussain RZ, Cravens PD, Doelger R, Greenberg BM, Okuda DT, Forsthuber TG, Eagar TN, Stüve O Journal of Neuroimmunology 2020 Jul 344
- The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis
  Milo R, Korczyn AD, Manouchehri N, Stüve O Multiple Sclerosis Journal 2020 Jul 26 876-886
- Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
  Foley JF, Stuve O Neurology: Neuroimmunology and NeuroInflammation 2020 May 7
- Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
  Goldman MD, Dwyer L, Coleman R, Sohn MW, Stuve O PloS one 2020 Feb 15
- Multiple Sclerosis
  Narayan RN, Stüve O, Shah A 2020 Jan 983-1005.e5
- Diclofenac reduces the risk of Alzheimer’s disease: a pilot analysis of NSAIDs in two US veteran populations
  Stuve O, Weideman RA, McMahan DM, Jacob DA, Little BB Therapeutic Advances in Neurological Disorders 2020 13
- Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
  Zhang Y, Gonzalez Caldito N, Shirani A, Salter A, Cutter G, Culpepper W, Wallin M, Kosa P, Bielekova B, Lublin F, Stϋve O Therapeutic Advances in Neurological Disorders 2020 13
- Trials and therapies in secondary progressive MS, simplified
  Manouchehri N, Stüve O Nature Reviews Neurology 2019 Aug 15 431-432
- α4-integrin deficiency in B cells does not affect disease in a T-cell-mediated EAE disease model
  Hussain RZ, Cravens PD, Miller-Little WA, Doelger R, Granados V, Herndon E, Okuda DT, Eagar TN, Stüve O Neurology: Neuroimmunology and NeuroInflammation 2019 Jul 6
- Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
  Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, Dangond F, Boschert U Therapeutic Advances in Neurological Disorders 2019 Jun 12
- Clinical trials in multiple sclerosis: potential future trial designs
  Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O Therapeutic Advances in Neurological Disorders 2019 May 12
- The role of B cells in multiple sclerosis: Current and future therapies
  Negron A, Robinson RR, Stuve O, Forsthuber TG Cellular Immunology 2019 May 339 10-23
- Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience
  Arendt G, Schlonies S, Orhan E, Stüve O Journal of NeuroVirology 2019 Apr 25 174-182
- Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis
  Berger T, Stuve O Neurology 2019 Mar 92 451-452
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
  Author Collaboration IC, Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG, Amato MP, Banwell B, Barkhof F, Bebo B, Becher B, Bethoux F, Brandt A, Brownlee W, Calabresi P, Chatway J, Chien C, Chitnis T, Comi G, Correale J, De Sèze J, De Stefano N, Fazekas F, Flanagan E, Freedman M, Fujihara K, Galetta S, Goldman M, Greenberg B, Hartung HP, Hemmer B, Henning A, Izbudak I, Kappos L, Lassmann H, Laule C, Levy M, Lublin F, Lucchinetti C, Lukas C, Marrie RA, Miller A, Miller D, Montalban X, Mowry E, Ourselin S, Paul F, Pelletier D, Ranjeva JP, Reich D, Reingold S, Stuve O The Lancet Neurology 2019 Feb 18 185-197
- Evolution of clinical trials in multiple sclerosis
  Zhang Y, Salter A, Wallström E, Cutter G, Stüve O Therapeutic Advances in Neurological Disorders 2019 Feb 12
- MaDCAM-1-mediated intestinal lymphocyte homing is critical for the development of active experimental autoimmune encephalomyelitis
  Kuhbandner K, Hammer A, Haase S, Terbrack E, Hoffmann A, Schippers A, Wagner N, Hussain RZ, Miller-Little WA, Koh AY, Stoolman JS, Segal BM, Linker RA, Stüve O Frontiers in immunology 2019 10
- Immunological aspects of approved MS therapeutics
  Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Stuve O Frontiers in immunology 2019 10
- TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency
  Hussain RZ, Cravens PC, Doelger R, Dentel B, Herndon E, Loof N, Tsai P, Okuda D, Racke MK, Stuve O Annals of Clinical and Translational Neurology 2018 Dec 5 1543-1561
- Natalizumab: Perspectives from the bench to bedside
  Shirani A, Stüve O Cold Spring Harbor Perspectives in Medicine 2018 Dec 8
- PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome
  Dubey D, Hussain RZ, Miller-Little WA, Salter A, Doelger R, Stüve O Journal of Neuroimmunology 2018 Oct 323 53-55
- Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis
  Cummings M, Arumanayagam AC, Zhao P, Kannanganat S, Stuve O, Karandikar NJ, Eagar TN PloS one 2018 Aug 13
- Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis
  Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BA, Oksenberg JR, Hauser SL, Baranzini SE Annals of Neurology 2018 Jul 84 51-63
- Similar biophysical abnormalities in glomeruli and podocytes from two distinct models
  Embry AE, Liu Z, Henderson JM, Byfield FJ, Liu L, Yoon J, Wu Z, Cruz K, Moradi S, Gillombardo CB, Hussain RZ, Doelger R, Stuve O, Chang AN, Janmey PA, Bruggeman LA, Miller RT Journal of the American Society of Nephrology 2018 May 29 1501-1512
- Emerging drugs for primary progressive multiple sclerosis
  Narayan RN, Forsthuber T, Stüve O Expert Opinion on Emerging Drugs 2018 Apr 23 97-110
- Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE
  Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O Neurology: Neuroimmunology and NeuroInflammation 2018 Mar 5
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
  Author Collaboration EC, Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F, Achiron A, Achtnichts L, Agan K, Akman-Demir G, Allen AB, Antel JP, Antiguedad AR, Apperson M, Applebee AM, Ayuso GI, Baba M, Bajenaru O, Balasa R, Balci BP, Barnett M, Bass A, Becker VU, Bejinariu M, Bergh FT, Bergmann A, Bernitsas E, Berthele A, Bhan V, Bischof F, Bjork RJ, Blevins G, Boehringer M, Boerner T, Bonek R, Bowen JD, Bowling A, Boyko AN, Boz C, Bracknies V, Braune S, Brescia Morra V, Stuve O The Lancet 2018 Mar 391 1263-1273
- B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
  Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O Therapeutic Advances in Neurological Disorders 2018 Jan 11
- Clinical trials in multiple sclerosis: milestones
  Zhang Y, Salter A, Cutter G, Stϋve O Therapeutic Advances in Neurological Disorders 2018 Jan 11
- B-cell-Targeted therapies in relapsing forms of MS
  Dubey D, Forsthuber T, Flanagan EP, Pittock SJ, Stüve O Neurology: Neuroimmunology and NeuroInflammation 2017 Oct 4
- Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache
  Stüve O, Cataldi F, Pradhan V, Gorelick KJ Journal of Neuroimmunology 2017 Sep 310 69-71
- Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease
  Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O Journal of Neuroimmunology 2017 Aug 309 100-110
- Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project
  Author Collaboration MR, Dickerson E, Davenport MS, Syed F, Stuve O, Cohen JA, Rinker JR, Goldman MD, Segal BM, Foerster BR Journal of the American College of Radiology 2017 Mar 14 371-379.e1
- Natalizumab for multiple sclerosis: A case in point for the impact of translational neuroimmunology
  Shirani A, Stüve O Journal of Immunology 2017 Feb 198 1381-1386
- High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
  Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD Neurology 2017 Feb 88 842-852
- The major histocompatibility complex and antibody-mediated limbic encephalitis
  Stüve O, Vernino S Annals of Neurology 2017 Feb 81 181-182
- Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
  Forsthuber TG, Stuve O Neurology: Neuroimmunology and NeuroInflammation 2016 Oct 3
- Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
  Menge T, Dubey D, Warnke C, Hartung HP, Stüve O Expert review of neurotherapeutics 2016 Oct 16 1131-1139
- IL-12/IL-23p40 is highly expressed in secondary lymphoid organs and the CNS during all stages of EAE, but its deletion does not affect disease perpetuation
  Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O PloS one 2016 Oct 11
- Diagnostic and therapeutic strategies for management of autoimmune encephalopathies
  Dubey D, Blackburn K, Greenberg B, Stuve O, Vernino S Expert review of neurotherapeutics 2016 Aug 16 937-949
- Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis
  Dubey D, Cano CA, Stüve O Current opinion in neurology 2016 Jun 29 272-277
- Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis
  Dubey D, Cano CA, Stüve O Current opinion in neurology 2016 Jun 29 278-285
- Managing Disability in Progressive Multiple Sclerosis
  Dubey D, Sguigna P, Stüve O Current Treatment Options in Neurology 2016 Jun 18
- Will biomarkers determine what is next in multiple sclerosis? Biomarkers in multiple sclerosis
  Stüve O, Racke MK JAMA neurology 2016 May 73 496-497
- Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’
  Leussink VI, Hartung HP, Stüve O, Kieseier BC Journal of neurology 2016 May 263 1027-1028
- Tumefactive demyelination following herbal supplement use: Cause or coincidence?
  Dubey D, Golden E, Suss A, Cano CA, Krishnan G, Stuve O Journal of postgraduate medicine 2016 Apr 62 136-137
- A single amino acid substitution prevents recognition of a dominant human aquaporin-4 determinant in the context of HLA-DRB1-03:01 by a murine TCR
  Arellano B, Hussain R, Miller-Little WA, Herndon E, Lambracht-Washington D, Eagar TN, Lewis R, Healey D, Vernino S, Greenberg BM, Stüve O PloS one 2016 Apr 11
- Primary progressive multiple sclerosis - Why we are failing
  Segal BM, Stüve O The Lancet 2016 Mar 387 1032-1034
- Acute relapse after initiation of Siponimod in a patient with secondary progressive MS
  Hussain R, O’Leary S, Pacheco FM, Zacharias TE, Litvak P, Sguigna P, Marder E, Kia K, Kooner K, Stüve O Journal of neurology 2016 Mar 263 606-610
- Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
  Shirani A, Okuda DT, Stüve O Neurotherapeutics 2016 Jan 13 58-69
- B cell-directed therapies in multiple sclerosis
  Gasperi C, Stüve O, Hemmer B Neurodegenerative disease management 2016 6 37-47
- Smoking beyond multiple sclerosis diagnosis: A risk factor still worth modifying
  Goldman MD, Stüve O JAMA neurology 2015 Oct 72 1105-1106
- The spectrum of autoimmune encephalopathies
  Dubey D, Sawhney A, Greenberg B, Lowden A, Warnack W, Khemani P, Stuve O, Vernino S Journal of Neuroimmunology 2015 Oct 287 93-97
- Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab
  Dubey D, Cano CA, Stuve O Neuropsychiatric Disease and Treatment 2015 Sep 11 2405-2414
- Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder
  Author Collaboration GC, Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, De Seze J, Wuerfel JT, Cabre P, Marignier R, Tedder T, Van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, Van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K JAMA neurology 2015 Jul 72 815-822
- Natalizumab to fingolimod: Questions answered, unanswered, and unasked
  Stüve O, Bourdette D Neurology 2015 Jul 85 14-15
- Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis - an observational study
  Author Collaboration tG, Rommer PS, Buckow K, Ellenberger D, Friede T, Pitschnau-Michel D, Fuge J, Stüve O, Zettl UK European Journal of Clinical Investigation 2015 Jun 45 587-593
- In Memoriam: Jean Lindenmann (1924-2015): A Circuitous Interfering Power in Neurology
  Stüve O JAMA neurology 2015 Jun 72 728-729
- B lymphocytes in neuromyelitis optica
  Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, Von Budingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C Neurology: Neuroimmunology and NeuroInflammation 2015 Jun 2 e104
- Demographic and clinical features of neuromyelitis optica: A review
  Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T, Iorio R, Würfel J, Paul F, Van Pelt D, Rogier H, Tedder T, Saiz A, Villoslada P, Levy M, Pandit L, Klawiter E, Weinshenker B, Wingerchuk D, Kim HJ, Tenembaum S, Palace J, Leite MI, Apiwattanakul M, Broadley S, Prayoonwiwat N, Kleiter I, Hellwig K, Han M, Banwell B, Van Herle K, Jacob A, Hooper C, Kazutoshi Sato D, Nakashima I, Fujihara K, Bichuetti D, Aktas O, De Seze J, Yeaman M, Waubant E, Zamvil S, Bennett J, Smith T, Lana-Peixoto M, Asgari N, Greenberg B, Stuve O Multiple Sclerosis Journal 2015 Jun 21 845-853
- Multiple sclerosis drugs: How much bang for the buck?
  Stüve O, Cutter GR The Lancet Neurology 2015 May 14 460-461
- Treatment decisions for patients with active multiple sclerosis
  Stüve O, Centonze D JAMA neurology 2015 Apr 72 387-389
- Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety
  Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O Expert review of neurotherapeutics 2015 Apr 15 339-346
- A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
  Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O Multiple Sclerosis Journal 2015 Mar 21 342-349
- The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
  Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N Multiple Sclerosis Journal 2015 Mar 21 305-317
- A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
  Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS Multiple Sclerosis Journal 2015 Mar 21 318-331
- A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
  Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M Multiple Sclerosis Journal 2015 Mar 21 282-293
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
  Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N Multiple Sclerosis Journal 2015 Mar 21 263-281
- The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
  Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J Multiple Sclerosis Journal 2015 Mar 21 332-341
- A systematic review of the incidence and prevalence of cancer in multiple sclerosis
  Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G Multiple Sclerosis Journal 2015 Mar 21 294-304
- Spinal gout: A rare cause of paraplegia
  Dubey D, Steen E, Sawhney A, Stuve O Neurology India 2015 Mar 63 284-285
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report
  Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD JAMA neurology 2015 Feb 72 159-169
- Update on biomarkers in neuromyelitis optica
  Author Collaboration G, Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti DB, Broadley SA, Cabre P, Chitnis T, de Sèze J, Fujihara K, Greenberg BM, Hellwig K, Iorio R, Klawiter EC, Kleiter I, Lana-Peixoto MA, Nakashima H, O'connor K, Palace J, Paul FA, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder TF, Tenembaum SN, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P Neurology: Neuroimmunology and NeuroInflammation 2015 2
- The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch
  Stüve O, Hemmer B Neurology: Neuroimmunology and NeuroInflammation 2014 Dec 1
- Heat exposure and bicycling trigger recurrent aseptic meningitis: A case report
  Stuve O, Marder E, Okai A, Stettner M, Kieseier BC BMC Neurology 2014 Dec 14
- Immune surveillance of the central nervous system in multiple sclerosis - Relevance for therapy and experimental models
  Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Deason K, Castro-Rojas C, Stüve O Journal of Neuroimmunology 2014 Nov 276 9-17
- Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance
  Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O Journal of Neuroimmunology 2014 Nov 276 232-235
- Isoniazid in autoimmunity: A trigger for multiple sclerosis?
  Nourbakhsh B, Stüve O Therapeutic Advances in Neurological Disorders 2014 Sep 7 253-256
- Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
  Cutter GR, Stüve O Multiple Sclerosis 2014 Sep 20 1304-1305
- CD19 as a molecular target in CNS autoimmunity
  Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, Von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V Acta Neuropathologica 2014 Aug 128 177-190
- Does natalizumab therapy benefit patients with multiple sclerosis?
  Stüve O, Cutter GR JAMA neurology 2014 Aug 71 945-946
- Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: In search of biomarkers
  Alvermann S, Hennig C, Stüve O, Wiendl H, Stangel M JAMA neurology 2014 Jul 71 905-912
- Defining the clinical course of multiple sclerosis: The 2013 revisions
  Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH Neurology 2014 Jul 83 278-286
- Alemtuzumab: The advantages and challenges of a novel therapy in MS
  Menge T, Stüve O, Kieseier BC, Hartung HP Neurology 2014 Jul 83 87-97
- Multiple sclerosis: Natalizumab to fingolimod - The washout whitewash
  Stangel M, Stüve O Nature Reviews Neurology 2014 Jun 10 311-313
- Para-dichlorobenzene toxicity - a review of potential neurotoxic manifestations
  Dubey D, Sharma VD, Pass SE, Sawhney A, Stüve O Therapeutic Advances in Neurological Disorders 2014 May 7 177-187
- Neuroinflammation of the central and peripheral nervous system: An update
  Stüve O, Zettl U Clinical and Experimental Immunology 2014 Mar 175 333-335
- Monoclonal antibodies in treatment of multiple sclerosis
  Rommer PS, Dudesek A, Stüve O, Zettl UK Clinical and Experimental Immunology 2014 Mar 175 373-384
- Requirement for safety monitoring for approved multiple sclerosis therapies: An overview
  Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg B, Hemmer B, Stuve O Clinical and Experimental Immunology 2014 Mar 175 397-407
- Multiple sclerosis disease progression and paradichlorobenzene a tale of mothballs and toilet cleaner
  Hession RM, Sharma V, Spiegel DE, Tat C, Hwang DG, Dieppa M, Mahdavi Z, Marder E, Stüve O JAMA neurology 2014 Feb 71 228-232
- Immunopathogenesis of Neuromyelitis Optica
  Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O Advances in Immunology 2014 121 213-242
- Body fluid biomarkers in multiple sclerosis: How far we have come and how they could affect the clinic now and in the future
  Raphael I, Webb J, Stuve O, Haskins W, Forsthuber T Expert review of clinical immunology 2014 Jan 11 69-91
- Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates
  Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O Expert review of clinical immunology 2014 Jan 11 93-108
- Teriflunomide for the treatment of multiple sclerosis
  Warnke C, Stüve O, Kieseier BC Clinical Neurology and Neurosurgery 2013 Dec 115 S90-S94
- A bird's-eye view of T cells during natalizumab therapy
  Hohlfeld R, Stüve O Neurology 2013 Oct 81 1372-1373
- Progressive multiple sclerosis: Desperately seeking remedy
  Stuve O, Paul F The Lancet Neurology 2013 Sep 12 840-841
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study
  Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E The Lancet Neurology 2013 Aug 12 756-767
- Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity
  Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS European Journal of Immunology 2013 Aug 43 2078-2088
- Management of secondary progressive multiple sclerosis: Prophylactic treatment - Past, present, and future aspects
  Rommer PS, Stüve O Current Treatment Options in Neurology 2013 Jun 15 241-258
- Teriflunomid zur Behandlung der Multiplen Sklerose
  Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC Nervenarzt 2013 Jun 84 724-731
- The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
  Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H Nature Reviews Neurology 2013 May 9 267-276
- The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
  Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O Journal of Neuroinflammation 2013 May 10
- Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica
  Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP JAMA neurology 2013 Mar 70 390-393
- Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis
  Greenberg B, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E JAMA neurology 2013 Feb 70 248-251
- A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease
  Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Eagar TN, Stüve O, Rosenberg RN Journal of Neuroimmunology 2013 Jan 254 63-68
- Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
  Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stüve O, Salvetti M, Centonze D European Journal of Neurology 2013 Jan 20 87-94
- A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation
  Rossi S, Motta C, Studer V, Monteleone F, De Chiara V, Buttari F, Barbieri F, Bernardi G, Battistini L, Cutter G, Stüve O, Salvetti M, Centonze D Multiple Sclerosis Journal 2013 Jan 19 59-68
- Objective characterization of the relative afferent pupillary defect in MS
  Blazek P, Davis SL, Greenberg B, Conger A, Conger D, Vernino S, Beh SC, Stuve O, Saidha S, Ratchford JN, Green A, Calabresi PA, Balcer LJ, Frohman TC, Frohman E Journal of the Neurological Sciences 2012 Dec 323 193-200
- Time to talk about timing - When to start, stop and change anti-migratory drugs in MS
  Stüve O, Hemmer B Multiple Sclerosis Journal 2012 Nov 18 1514-1516
- Treatment of neuromyelitis optica: Review and recommendations
  Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Isabel Leite M, Levy M, Marignier R, Nakashima I, Palace J, De Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM Multiple Sclerosis and Related Disorders 2012 Oct 1 180-187
- Cerebral and cervical venous outflow abnormalities are dynamic
  Marder E, Gupta P, Ragland M, Stüve O Archives of neurology 2012 Oct 69 1380-1381
- Human aquaporin 4 _281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: Relevance for diagnosing and monitoring patients with neuromyelitis optica
  Arellano B, Hussain R, Zacharias T, Yoon J, David C, Zein S, Steinman L, Forsthuber T, Greenberg BM, Lambracht-Washington D, Ritchie AM, Bennett JL, Stüve O Archives of neurology 2012 Sep 69 1125-1131
- Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success
  Greenberg B, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson NL, Frohman E Multiple Sclerosis Journal 2012 Jul 18 1022-1026
- Cytokine levels in CSF and neuropsychological performance in HIV patients
  Nolting T, Lindecke A, Hartung HP, Koutsilieri E, Maschke M, Husstedt IW, Sopper S, Stüve O, Arendt G Journal of NeuroVirology 2012 Jun 18 157-161
- Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study
  Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS Neurology 2012 Apr 78 1171-1178
- From injection therapies to natalizumab: Views on the treatment of multiple sclerosis
  Bomprezzi R, Okuda D, Alderazi YJ, Stüve O, Frohman E Therapeutic Advances in Neurological Disorders 2012 Mar 5 97-104
- Firategrast-natalizumab in a pill?
  Prat A, Stüve O The Lancet Neurology 2012 Feb 11 120-121
- CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke
  Stowe AM, Wacker BK, Cravens PD, Perfater JL, Li MK, Hu R, Freie AB, Stüve O, Gidday JM Journal of Neuroinflammation 2012 Feb 9
- Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects
  Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, Hemmer B, Stüve O Current Pharmaceutical Design 2012 Feb 18 209-219
- Immune-mediated CNS diseases: A review on nosological classification and clinical features
  Zettl UK, Stüve O, Patejdl R Autoimmunity Reviews 2012 Jan 11 167-173
- No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis
  Marder EJ, Gupta P, Greenberg B, Frohman E, Awad AM, Bagert B, Stuve O Archives of neurology 2011 Dec 68 1521-1525
- Multiple sclerosis: Combination therapy in MS-still a valid strategy
  Kieseier BC, Stüve O Nature Reviews Neurology 2011 Dec 7 659-660
- Chronic cerebrospinal venous insufficiency and multiple sclerosis
  Bagert BA, Marder E, Stüve O Archives of neurology 2011 Nov 68 1379-1384
- Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
  Warnke C, Stüve O, Hartung HP, Fogdell-Hahn A, Kieseier BC Neuropsychiatric Disease and Treatment 2011 Nov 7 519-527
- Idiopathic transverse myelitis and neuromyelitis optica: Clinical profiles, pathophysiology and therapeutic choices
  Awad A, Stüve O Current Neuropharmacology 2011 Sep 9 417-428
- DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.
  Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Stüve O, Eagar TN, Rosenberg RN Cellular and Molecular Neurobiology 2011 Aug 31 867-874
- Multiple sclerosis and chronic cerebrospinal venous insufficiency: A critical review
  Awad AM, Marder E, Milo R, Stüve O Therapeutic Advances in Neurological Disorders 2011 Jul 4 231-235
- The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors
  Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stüve O Autoimmunity Reviews 2011 Jun 10 495-502
- Lymph node-derived donor encephalitogenic CD4⁺T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet
  Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O Journal of Neuroinflammation 2011 Jun 8
- Risks and benefits of multiple sclerosis therapies: Need for continual assessment?
  Kieseier BC, Wiendl H, Hartung HP, Leussink VI, Stüve O Current opinion in neurology 2011 Jun 24 238-243
- A critical appraisal of treatment decisions in multiple sclerosisĝ€"old versus new
  Kieseier BC, Stüve O Nature Reviews Neurology 2011 May 7 255-262
- Symptomatic therapy in multiple sclerosis
  Frohman TC, Castro W, Shah A, Ortstadt JL, Ortstadt J, Davis SL, Logan D, Abraham T, Abraham J, Remington G, Treadaway K, Greenberg B, Shah A, Hart J, Stuve O, Lemack GE, Frohman E Therapeutic Advances in Neurological Disorders 2011 Mar 4 83-98
- No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis
  Stüve O, Wang J, Chan A, Hemmer B, Cepok S, Nessler S, Zipp F, Goldman MD, Meuth SG, Korth C, Lambracht-Washington D Archives of neurology 2011 Feb 68 264-265
- Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis
  Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, Martin Md, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN PloS one 2011 6
- Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules
  Meyer zu Hörste G, Mausberg AK, Müller JI, Lehmann HC, Löber S, Gmeiner P, Hartung HP, Stüve O, Korth C, Kieseier BC PloS one 2011 6
- Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death
  Herrmann AM, Göbel K, Simon OJ, Melzer N, Schuhmann MK, Stenner MP, Weishaupt A, Kleinschnitz C, Bittner S, Meuth P, Stuve O, Budde T, Kieseier BC, Wiendl H, Meuth SG American Journal of Pathology 2010 Dec 177 3051-3060
- The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon?
  Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stüve O CNS Neuroscience and Therapeutics 2010 Dec 16 362-373
- Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine
  Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC Drug Design, Development and Therapy 2010 Dec 4 117-126
- Translational research in neurology and neuroscience 2010: Multiple sclerosis
  Stuve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman E, Greenberg B, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder EJ, Khan O, Eagar TN Archives of neurology 2010 Nov 67 1307-1315
- Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4⁺ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein
  Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg B, Racke MK, Cowell LG, Karandikar NJ, Frohman E, Monson NL European Journal of Immunology 2010 Oct 40 2942-2956
- Immunopathogenesis of multiple sclerosis: New insights and therapeutic implications
  Awad AM, Stüve O CONTINUUM Lifelong Learning in Neurology 2010 Oct 16 166-180
- Reversible alopecia associated with glatiramer acetate
  Pacheco MF, Jacobe H, Eagar TN, Stüve O Archives of neurology 2010 Sep 67 1154
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
  Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T Annals of Neurology 2010 Sep 68 409-411
- Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?
  Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman E, Greenberg B, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stuve O Archives of neurology 2010 Aug 67 923-930
- Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's disease
  Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN Vaccine 2010 Jul 28 5280-5287
- Quinpramine - A promising compound for treating immune-mediated demyelination of the nervous system
  Meyer Zu Hörste G, Mausberg AK, Korth C, Stüve O, Kieseier BC Drug News and Perspectives 2010 Jun 23 287-294
- Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial
  Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, Bourdette D Multiple Sclerosis 2010 Jun 16 715-723
- Anticipated benefits and surprising effects of daclizumab in multiple sclerosis
  Stüve O, Greenberg BM The Lancet Neurology 2010 Apr 9 337-338
- Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
  Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O Journal of Neuroimmunology 2010 Feb 219 1-7
- Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling
  Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O Brain 2010 Feb 133 375-388
- Reply
  Berthele A, Schweikert A, Stüve O, Hemmer B Annals of Neurology 2010 Feb 67 271
- Immunomodulation in multiple sclerosis
  Leussink VI, Stüve O, Hö;rste GM, Kieseier BC Hot Topics in Neurology and Psychiatry 2010 17-21
- A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)
  Remington GM, Treadaway K, Frohman T, Salter A, Stuve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman E Therapeutic Advances in Neurological Disorders 2010 Jan 3 3-13
- A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
  Frohman E, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Stuve O, Greenberg B, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Shah A, Greenberg BM, Racke MK, Zivadinov R Therapeutic Advances in Neurological Disorders 2010 Jan 3 15-28
- Optic neuritis presenting with amaurosis fugax
  Awad AM, Estephan B, Warnack W, Stüve O Journal of neurology 2009 Dec 256 2100-2103
- Direct and consensual murine pupillary reflex metrics: Establishing normative values
  Hussain RZ, Hopkins SC, Frohman EM, Eagar TN, Cravens PC, Greenberg BM, Vernino S, Stüve O Autonomic Neuroscience: Basic and Clinical 2009 Dec 151 164-167
- The future of multiple sclerosis therapy
  Kieseier BC, Wiendl H, Hartung HP, Stüve O Pharmacological Research 2009 Oct 60 207-211
- Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?
  Stüve O, Wiendl H Neurology 2009 Oct 73 1346-1347
- Depletion of B lymphocytes from cerebral perivascular spaces by rituximab
  Martin MD, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman E, Kleinschmidt-DeMasters BK, Montine TJ, Hemmer B, Marra CM, Stuve O Archives of neurology 2009 Aug 66 1016-1020
- A 69-year-old man with left hemispheric necrotizing mass lesion: Com March 2009 case 2
  Otto F, Neuen-Jacob E, Arendt G, Stüve O, Hartung HP Brain Pathology 2009 Jul 19 541-544
- Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: Therapeutic implications
  Bennett JL, Stüve O Clinical neuropharmacology 2009 May 32 121-132
- Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity
  Hofstetter HH, Stüve O, Hartung HP Experimental Neurology 2009 May 217 4-6
- Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-α agonists in autoimmune disease
  Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK Journal of Immunology 2009 Apr 182 4479-4487
- Factors that influence adherence with disease-modifying therapy in MS
  Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder EJ, Allen A, Harney J, Cooper J, Woo D, Stuve O, Racke M, Frohman E Journal of neurology 2009 Apr 256 568-576
- 200 years after darwin
  Rosenberg RN, Stüve O, Eagar T Archives of neurology 2009 Feb 66 153-155
- 200 years after darwin
  Rosenberg RN, Stüve O, Eagar T JAMA 2009 Feb 301 660-662
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
  Stuve O, Cravens PD, Frohman E, Phillips JT, Remington GM, Von Geldern G, Cepok S, Singh MP, Cohen Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK Neurology 2009 Feb 72 396-401
- Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis
  Stuve O, Korth C, Gabatto P, Cameron EM, Hu W, Eagar TN, Monson NL, Frohman E, Racke MK, Zabetian CP, Oksenberg JR Archives of neurology 2009 Feb 66 280-281
- Visualizing the cause of gray matter atrophy in multiple sclerosis
  Richert ND, Kraft E, Stüve O Archives of neurology 2009 Feb 66 159-160
- Quinpramine is a novel compound effective in ameliorating brain autoimmune disease
  Singh MP, Hörste GM, Hu W, Mausberg AK, Cravens PD, Eagar T, Löber S, Klingenstein R, Gmeiner P, Korth C, Kieseier BC, Stüve O Experimental Neurology 2009 Feb 215 397-400
- Knowns and unknowns in the future of multiple sclerosis treatment
  Stüve O Journal of the Neurological Sciences 2009 287 S30-S36
- Review of teriflunomide and its potential in the treatment of multiple sclerosis
  Warnke C, Zu Hörste GM, Hartung HP, Stüve O, Kieseier BC Neuropsychiatric Disease and Treatment 2009 5 333-340
- Immunotherapy for multiple sclerosis: The curious case of interferon beta
  Stüve O, Ransohoff RM Archives of neurology 2009 66 1193-1194
- Primary central nervous system lymphoma in a patient treated with natalizumab
  Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stüve O, Hemmer B, Berthele A Annals of Neurology 2009 66 403-406
- DNA β-amyloid_1-42 trimer immunization for alzheimer diseaseina wild-type mouse model
  Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN JAMA 2009 302 1796-1802
- PEG minocycline-liposomes ameliorate CNS autoimmune disease
  Hu W, Metselaar J, Ben LH, Cravens PD, Singh MP, Frohman E, Eagar TN, Racke MK, Kieseier BC, Stuve O PloS one 2009 Jan 4
- Monoclonal antibodies in the therapy of multiple sclerosis: AAAn overview
  Rommer PS, Stüve O, Goertsches R, Mix E, Zettl UK Journal of neurology 2008 Dec 255 28-35
- Decrease in the numbers of dendritic cells and CD4 ⁺ T cells in cerebral perivascular spaces due to natalizumab
  Del Pilar Martin M, Cravens PD, Winger R, Frohman E, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stuve O Archives of neurology 2008 Dec 65 1596-1603
- Immunomodulatory treatment strategies in multiple sclerosis
  Kieseier BC, Wiendl H, Leussink VI, Stüve O Journal of Neurology 2008 Dec 255 15-21
- α4-Integrin antagonism with natalizumab: EEEffects and adverse effects
  Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC Journal of neurology 2008 Dec 255 58-65
- Immunosuppression in clinical practice: AAApproaches to individualized therapy
  Chan A, Stüve O, Von Ahsen N Journal of neurology 2008 Dec 255 22-27
- The effects of natalizumab on the innate and adaptive immune system in the central nervous system
  Stüve O Journal of the Neurological Sciences 2008 Nov 274 39-41
- Immunologic Mechanisms of Multiple Sclerosis
  Frohman E, Eagar T, Monson NL, Stuve O, Karandikar N Neuroimaging Clinics of North America 2008 Nov 18 577-588
- Fine-tuning the homeostasis of regulatory T cells: New mechanism of immunomodulatory therapy in multiple sclerosis
  Hofstetter HH, Stüve O, Hartung HP Archives of neurology 2008 Nov 65 1417-1418
- Natalizumab: Increased vigilance is required in treating patients with multiple sclerosis
  Racke MK, Stüve O Therapeutic Advances in Neurological Disorders 2008 Nov 1 155-156
- B cells, antibodies, and tertiary lymphoid tissue in MS brains
  Stüve O, Eagar TN The Lancet Neurology 2008 Sep 7 766-767
- Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab: Evidence for disease heterogeneity
  Leussink VI, Lehmann HC, Meyer Zu Hörste G, Hartung HP, Stüve O, Kieseier BC Journal of neurology 2008 Sep 255 1436-1438
- Temporary leukocyte effects in temporal lobe epilepsy?
  Hofstetter HH, Stüve O, Hartung HP Experimental Neurology 2008 Aug 212 239-241
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
  Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman E, Khan O Neurology 2008 Jul 71 136-144
- Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients
  Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson NL, Racke MK, Jacobson S PloS one 2008 Apr 3
- DNA-based vaccines: The future of multiple sclerosis therapy?
  Stüve O, Cravens PD, Eagar TN Expert review of neurotherapeutics 2008 Mar 8 351-360
- Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis
  Davis SL, Frohman TC, Crandall CG, Brown MJ, Mills DA, Kramer PD, Stuve O, Frohman E Neurology 2008 Mar 70 1098-1106
- Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician
  Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O The Lancet Neurology 2008 Feb 7 173-183
- Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? [1]
  Nash RA, Stuve O, Bowen JD, Frohman E, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA Brain 2008 Feb 131 e89
- Pharmacological treatment of early multiple sclerosis
  Stuve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman E Drugs 2008 68 73-83
- Prion proteins: Physiological functions and role in neurological disorders
  Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, Hartung HP, Stuve O Journal of the Neurological Sciences 2008 Jan 264 1-8
- Modeling axonal degeneration within the anterior visual system: Implications for demonstrating neuroprotection in multiple sclerosis
  Frohman E, Costello F, Stuve O, Calabresi P, Miller DH, Hickman SJ, Sergott R, Conger A, Salter A, Hoggatt KA, Frohman TC, Balcer L, Zivadinov R Archives of neurology 2008 Jan 65 26-35
- Disease-modifying agents for multiple sclerosis: Recent advances and future prospects
  Menge T, Weber MS, Hemmer B, Kieseier BC, Von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O Drugs 2008 68 2445-2468
- The death domain-containing kinase RIP1 regulates p27^Kip1 levels through the PI3K-Akt-forkhead pathway
  Park S, Ramnarain DB, Hatanpaa KJ, Mickey BE, Saha D, Paulmurugan R, Madden CJ, Wright PS, Bhai S, Ali MA, Puttaparthi K, Hu W, Elliott JL, Stuve O, Habib AA EMBO Reports 2008 9 766-773
- Multiple sclerosis therapy: An update on recently finished trials
  Kleinschnitz C, Meuth SG, Stüve O, Kieseier B, Wiendl H Journal of neurology 2007 Nov 254 1473-1490
- Corticosteroids for Multiple Sclerosis: II. Application for Disease-Modifying Effects
  Shah A, Eggenberger E, Zivadinov R, Stuve O, Frohman E Neurotherapeutics 2007 Oct 4 627-632
- DNA plasmid vaccination for multiple sclerosis
  Stuve O, Eagar TN, Frohman E, Cravens PD Archives of neurology 2007 Oct 64 1385-1386
- Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations
  Frohman E, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O Neurotherapeutics 2007 Oct 4 618-626
- Spotlight on statins
  Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS International MS Journal 2007 Sep 14 93-97
- Humoral immune responses after rabies infection [1]
  Watson NF, Woo D, Doherty MJ, Frohman E, Racke MK, De Baets M, Hartung HP, Kieseier BC, Stuve O Archives of neurology 2007 Sep 64 1355-1356
- Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
  Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS Nature medicine 2007 Aug 13 935-943
- Prion proteins: A biological role beyond prion diseases
  Hu W, Rosenberg RN, Stüve O Acta Neurologica Scandinavica 2007 Aug 116 75-82
- High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: Role of intrathecal leukocytes [1]
  Stuve O, Cravens PD, Singh MP, Frohman E, Phillips JT, Remington G, Hu W, Hemmer B, Olek MJ, Monson NL, Racke MK Archives of neurology 2007 Jul 64 1055-1056
- Combination therapies for multiple sclerosis: Scientific rationale, clinical trials, and clinical practice
  Costello F, Stuve O, Weber MS, Zamvil SS, Frohman E Current opinion in neurology 2007 Jun 20 281-285
- Acute disseminated encephalomyelitis: An acute hit against the brain
  Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O Current opinion in neurology 2007 Jun 20 247-254
- Revised criteria for neuromyelitis optica - A new diagnostic standard? Commentary
  Hemmer B, Stüve O Nature Clinical Practice Neurology 2007 Mar 3 132-133
- Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases
  Stüve O, Bennett JL CNS Drug Reviews 2007 Mar 13 79-95
- W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century.
  Frohman E, Stuve O, Miller DH Archives of neurology 2007 Mar 64 452-454
- Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions
  Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Cohen Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman E, Hemmer B Archives of neurology 2007 Feb 64 169-176
- Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis
  Kopadze T, Dehmel T, Hartung HP, Stüve O, Kieseier BC Archives of neurology 2006 Nov 63 1572-1578
- Optical coherence tomography in multiple sclerosis
  Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, Balcer L Lancet Neurology 2006 Oct 5 853-863
- Statins in the treatment of central nervous system autoimmune disease
  Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS Journal of Neuroimmunology 2006 Sep 178 140-148
- Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders
  Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC Archives of neurology 2006 Aug 63 1066-1071
- Statins and the blood-brain barrier: Plugging the holes
  Stüve O Annals of Neurology 2006 Jul 60 1-2
- Central nervous system infections - A potential complication of systemic immunotherapy
  Hemmer B, Frohman E, Hartung HP, Stuve O Current Opinion in Neurology 2006 Jun 19 271-276
- Immune surveillance in multiple sclerosis patients treated with natalizumab
  Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman E, Phillips T, Arendt G, Hemmer B, Monson NL, Racke MK Annals of Neurology 2006 May 59 743-747
- Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis
  Frohman E, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M Archives of neurology 2006 Apr 63 614-619
- Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
  Stüve O, Youssef S, Weber MS, Nessler S, Von Büdingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS Journal of Clinical Investigation 2006 Apr 116 1037-1044
- Prion protein gene codon 129 modulates clinical course of neurological Wilson disease
  Grubenbecher S, Stüve O, Hefter H, Korth C NeuroReport 2006 Apr 17 549-552
- Altered CD4⁺/CD8⁺ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
  Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman E, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK Archives of neurology 2006 63 1383-1387
- Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders
  Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC Archives of neurology 2006 63 930-935
- Therapeutic potential of small interfering RNA for central nervous system diseases
  Lovett-Racke AE, Cravens PD, Gocke AR, Racke MK, Stüve O Archives of neurology 2005 Dec 62 1810-1813
- Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro
  Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stüve O, Hartung HP Journal of Neuroimmunology 2005 Nov 168 128-137
- Acute disseminated encephalomyelitis: An update
  Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, Kieseier BC, Stüve O Archives of neurology 2005 Nov 62 1673-1680
- Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations
  Frohman E, Stuve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M Archives of neurology 2005 Oct 62 1519-1530
- Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis
  Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, Kieseier BC Archives of neurology 2005 Oct 62 1620-1623
- Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions
  Frohman E, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson NL, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK Archives of neurology 2005 Sep 62 1345-1356
- Immune response to immunotherapy: The role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis
  Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP Lancet Neurology 2005 Jul 4 403-412
- Putative mechanisms of action of statins in multiple sclerosis - Comparison to interferon-β and glatiramer acetate
  Neuhaus O, Stüve O, Archelos JJ, Hartung HP Journal of the Neurological Sciences 2005 Jun 233 173-177
- Akute disseminierte enzephalomyelitis. Pathogenese, diagnose, behandlung und prognose
  Stüve O, Nessler S, Hartung HP, Hemmer B, Wiendl H, Kieseier BC Nervenarzt 2005 Jun 76 701-707
- Statine zur behandlung von erkrankungen des zentralen nervensystems. Eine standortbestimmung aus forschung und klinik
  Menge T, Von Büdingen HC, Zamvil SS, Hartung HP, Kieseier BC, Stüve O Nervenarzt 2005 Apr 76 426-437
- Statins - A cure-all for the brain?
  Menge T, Hartung HP, Stüve O Nature Reviews Neuroscience 2005 Apr 6 325-331
- The role of astrocytes in autoimmune disease of the central nervous system
  Stüve O, Zamvil SS 2005 85-108
- Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: Opportunities and obstacles
  Neuhaus O, Stüve O, Zamvil SS, Hartung HP CNS Drugs 2005 19 833-841
- Viral pathogens in multiple sclerosis: An intriguing (hi)story
  Stüve O, Racke M, Hemmer B Archives of neurology 2004 Oct 61 1500-1502
- Mitoxantrone as a potential therapy for primary progressive multiple sclerosis
  Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil SS Multiple Sclerosis 2004 Jun 10 S58-S61
- Are statins a treatment option for multiple sclerosis?
  Neuhaus O, Stüve O, Zamvil SS, Hartung HP Lancet Neurology 2004 Jun 3 369-371
- Statins as potential therapeutic agents in multiple sclerosis
  Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS Current neurology and neuroscience reports 2004 May 4 237-244
- The potential therapeutic role of statins in central nervous system autoimmune disorders
  Stüve O, Youssef S, Dunn S, Slavin AJ, Steinman L, Zamvil SS Cellular and Molecular Life Sciences 2003 Nov 60 2483-2491
- Statins and their potential targets in multiple sclerosis therapy
  Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS Expert Opinion on Therapeutic Targets 2003 Oct 7 613-622
- Statins as potential therapeutic agents in neuroinflammatory disorders
  Stüve O, Youssef S, Steinman L, Zamvil SS Current opinion in neurology 2003 Jun 16 393-401
- The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease
  Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS Journal of Immunology 2002 Dec 169 6720-6732
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
  Youssef S, Stüve O, Patarroyo JO, Ruiz PJ, Radosevich JL, Mi Hur E, Bravo M, Mitchell DJ, Sobel RA, Stelnman L, Zamvil SS Nature 2002 Nov 420 78-84
- Approved and future pharmacotherapy for multiple sclerosis
  Stüve O, Cree BC, Von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS Neurologist 2002 Sep 8 290-301
- Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate
  Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS Journal of Immunology 2002 Sep 169 2231-2235
- Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA)
  Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS Genes and Immunity 2002 Feb 3 34-37
- Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity
  Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana A, Bikoff EK, Zamvil SS Journal of Clinical Investigation 2001 108 1133-1139
- Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-γ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4⁺ T-cell activation
  Soos JM, Krieger JI, Stüve O, King CL, Patarroyo JC, Aldape K, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS GLIA 2001 36 391-405
- The absence of interictal spikes with documented seizures suggests extratemporal epilepsy
  Stüve O, Dodrill CB, Holmes MD, Miller JW Epilepsia 2001 42 778-781
- Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor
  Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, Kashyap A, McSweeney P, Forman S Neurology 2000 Jun 54 2147-2150
- Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis
  Stüve O, Zamvil SS Current opinion in neurology 1999 12 395-401
- Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β-1b therapy
  Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, Antel JP, Yong VW Annals of Neurology 1999 46 319-324
- Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
  Yong VW, Chabot S, Stuve O, Williams G Neurology 1998 Sep 51 682-689
- Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9
  Stuve O, Chabot S, Jung SS, Williams G, Yong VW Journal of Neuroimmunology 1997 Dec 80 38-46
- Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
  Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW Annals of Neurology 1996 Dec 40 853-863
- The value of routine computed tomography of the brain in the pre-operative assessment of patients for carotid endarterectomy
  Stuve O, Louwrens H, Hill J, Immelman EJ South African Medical Journal 1996 Nov 86 1420-1422

Research

Molecular and cellular markers of autoimmunity
Immune tolerance
Experimental therapies for autoimmune disorders

New Patient Appointment or 214-645-8800